$TENX Cantor Fitzgerald Reiterates rating and $35 Price Target

$TENX Cantor Fitzgerald Reiterates rating and $35 Price Target Shares are currently trading at $1.95 with the market cap currently at 72.98M Today, Cantor comes blazing in and reiterates with an overweight rating and $35 price target! Add the fact that expert bio investor Dr. Daniel Schneeberger recently added heavily to his existing position with Adar1 Capital Management and now his shares total 6,524,151 to date. Details from the presentation yesterday at the 2026 Cantor Global Healthcare Conference $TENX What we confirmed • Oral levosimendan is safe and well-tolerated , with 1mg BID/TID providing PK concentrations expected • Targeting volume with K-ATP channel activation has direct effects on NT-proBNP and RVSP, two prespecified endpoints • Treatment effect seen in HELP study validated • Successful trial execution by sites and clinical development team ——-> What we learned • Drug effect is evident in patients with higher disease burden • Study entry criteria allowed patients with moderate disease and little room to improve in 6MWD • In patients with baseline 6MWD\* < 333 m, treatment effect was +26.3 m vs placebo (95% Cl: 6.0, 46.7; nominal p = 0.112) • In the overall population NT-pro-BNP was reduced by 49% vs placebo (nominal p = 0.0001) ——-> What we are doing now Enriching LEVEL-2